Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...

Pancreatic cancer is one of the deadliest malignancies, with survival rates remaining dismally low despite major advances in ...

Stress affects many systems in our body and biologists Marcel Schaaf and Erin Faught at Radboud University are figuring out ...

Rezolute said on Thursday its therapy aimed at controlling excessive insulin activity in patients with a rare genetic disorder did not show significant benefit in a late-stage trial.

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

New psychoactive substances, originally developed as potential analgesics but abandoned due to adverse side effects, may ...

An international team involving the Institute of Chemical Research, a joint center of the University of Seville and the Spanish National Research Council, has developed a new technique that will ...